Precision medicine advances in idiopathic pulmonary fibrosisΤheodoros Karampitsakos, Jose D. Herazo‐Maya, Brenda Juan-Guardela et al.|EBioMedicine|2023Cited by 150
Monocytes and macrophages: emerging mechanisms and novel therapeutic targets in pulmonary fibrosisCarole Y. Perrot, Jose D. Herazo‐Maya, Τheodoros Karampitsakos|American Journal of Physiology-Cell Physiology|2023Cited by 82
Expression of PD-1/PD-L1 axis in mediastinal lymph nodes and lung tissue of human and experimental lung fibrosis indicates a potential therapeutic target for idiopathic pulmonary fibrosisΤheodoros Karampitsakos, Argyris Tzouvelekis, Apostolos Galaris et al.|Respiratory Research|2023Cited by 30
The Dawn of Precision Medicine in Fibrotic Interstitial Lung DiseaseΤheodoros Karampitsakos, Jose D. Herazo‐Maya, Bochra Tourki|CHEST Journal|2024Cited by 24
Convergent and divergent immune aberrations in COVID-19, post-COVID-19-interstitial lung disease, and idiopathic pulmonary fibrosisBochra Tourki, Jose D. Herazo‐Maya, Minxue Jia et al.|American Journal of Physiology-Cell Physiology|2024Cited by 9